Litcius/Paper detail

Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial

Arvinder S. Soin, Kuldeep Kumar, Narendra S. Choudhary, Pooja Sharma, Yatin Mehta, Sushila Kataria, Deepak Govil, Vikas Deswal, Dhruva Chaudhry, Pawan Singh, Ashish Gupta, Vikas Agarwal, Suresh Kumar, Shashikala Sangle, Rajesh Chawla, Suneetha Narreddy, Rahul Pandit, Vipul Kumar Mishra, Manoj Goel, Athimalaipet V Ramanan

2021The Lancet Respiratory Medicine237 citationsDOIOpen Access PDF

Topics & Concepts

TocilizumabMedicineClinical endpointPopulationInternal medicineRandomized controlled trialClinical trialAdverse effectCytokine release syndromeCoronavirus disease 2019 (COVID-19)Rheumatoid arthritisEnvironmental healthInfectious disease (medical specialty)DiseaseCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19SARS-CoV-2 and COVID-19 Research
Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial | Litcius